- Home
- LGVN vs ATHA Comparison
LGVN vs ATHA Comparison
Compare LGVN & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- ATHA
- Stock Information
- Founded
- LGVN 2014
- ATHA 2011
- Country
- LGVN United States
- ATHA United States
- Employees
- LGVN N/A
- ATHA N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- LGVN Health Care
- ATHA Health Care
- Exchange
- LGVN Nasdaq
- ATHA Nasdaq
- Market Cap
- LGVN 16.6M
- ATHA 14.8M
- IPO Year
- LGVN 2021
- ATHA 2020
- Fundamental
- Price
- LGVN $0.79
- ATHA $0.36
- Analyst Decision
- LGVN Strong Buy
- ATHA Hold
- Analyst Count
- LGVN 2
- ATHA 3
- Target Price
- LGVN $6.50
- ATHA $0.50
- AVG Volume (30 Days)
- LGVN 496.8K
- ATHA 159.8K
- Earning Date
- LGVN 11-11-2025
- ATHA 11-06-2025
- Dividend Yield
- LGVN N/A
- ATHA N/A
- EPS Growth
- LGVN N/A
- ATHA N/A
- EPS
- LGVN N/A
- ATHA N/A
- Revenue
- LGVN $2,073,000.00
- ATHA N/A
- Revenue This Year
- LGVN N/A
- ATHA N/A
- Revenue Next Year
- LGVN N/A
- ATHA N/A
- P/E Ratio
- LGVN N/A
- ATHA N/A
- Revenue Growth
- LGVN 68.67
- ATHA N/A
- 52 Week Low
- LGVN $0.63
- ATHA $0.22
- 52 Week High
- LGVN $2.48
- ATHA $0.83
- Technical
- Relative Strength Index (RSI)
- LGVN 37.95
- ATHA 36.59
- Support Level
- LGVN $0.78
- ATHA $0.35
- Resistance Level
- LGVN $0.85
- ATHA $0.40
- Average True Range (ATR)
- LGVN 0.05
- ATHA 0.02
- MACD
- LGVN 0.02
- ATHA -0.00
- Stochastic Oscillator
- LGVN 46.30
- ATHA 11.86
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.